RPRX 最新10-Q变化
将 RPRX 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-05-06 与上一份 10-Q · 2025-11-05
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +82 | −110 | ~44 | 47 |
| 市场风险(第3项) | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
| 控制与程序 | 文字有新增/删除 | +1 | −2 | ~2 | 0 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 部分风险因素更新 | +24 | −21 | ~54 | 161 |
| 其他信息 | 文字有新增/删除 | +2 | 0 | ~1 | 1 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-05-06
1.Approximately 22.8 million RP Holdings Class E Interests with an aggregate fair value of approximately $755.4 million, which are expensed over vesting periods on a straight-line basis of generally five to nine years. As of March 31, 2026, we had $609.8 million of unrecognized compensation expense …
Our historical results of operations for 2025 have been recast to reflect the adoption of ASU 2025-07 by removing the losses previously recognized on derivative. The comparison of our historical results of operations is as follows (in thousands):
Provision for changes in expected cash flows from financial royalty assets(197,485)(127,140)(70,345)55.3
Provision for credit losses on unfunded commitments(3,700)— (3,700)n/a
Income from financial royalty assets by top products is as follows, in order of contribution to income for the first quarter of 2026 (in thousands):
相对上期删除的文字 · 来源:10-Q · 2025-11-05
For the Three Months Ended September 30,For the Nine Months Ended September 30,
Other royalty income and revenues also includes revenues from intangible royalty assets and income from royalties that are recorded at fair value.
1.Approximately 22.8 million RP Holdings Class E Interests with an aggregate fair value of approximately $755.4 million which are expensed over vesting periods on a straight-line basis of generally five to nine years.
The comparison of our historical results of operations is as follows (in thousands):
For the Three Months Ended September 30,ChangeFor the Nine Months Ended September 30,Change
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-05-06
A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issue…
相对上期删除的文字 · 来源:10-Q · 2025-11-05
In accordance with guidance issued by the Securities and Exchange Commission, companies are allowed to exclude acquired businesses from the assessment of internal control over financial reporting during the first year after completion of an acquisition. Accordingly, we expect to exclude the portion …
A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issue…
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-05-06
•risks related to the growth and dynamics of the royalty market;
•uncertainties related to acquiring interests in development-stage biopharmaceutical product candidates;
•potential strategic acquisitions of operating biopharmaceutical companies;
•our ability to generate increasing royalty receipts and to achieve attractive returns on our investments, including maintaining attractive internal rates of return and consistent returns on invested capital and returns on invested equity;
•marketers of products that generate our royalties are outside of our control;
相对上期删除的文字 · 来源:10-Q · 2025-11-05
•uncertainties related to the acquisition of interests in development-stage biopharmaceutical product candidates and our strategy to add interests in development-stage product candidates to our product portfolio;
•potential strategic acquisitions of biopharmaceutical companies;
•marketers of products that generate our royalties are outside of our control and are responsible for development, pursuit of ongoing regulatory approval, commercialization, manufacturing and marketing;
Biopharmaceutical product sales may be lower than expected due to a number of reasons, including pricing pressures, insufficient demand, product competition, failure of clinical trials, lack of market acceptance, changes in the marketer’s strategic priorities, obsolescence, lack of acceptance by hea…
Other events that affect the banking industry may adversely affect the banking institutions that hold our cash. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits. In the event of a bank insolvency or failure, we may be considered a general creditor …
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-05-06
(2)Maximum shares subject to trading plan consists of up to 214,091 Class A ordinary shares and 100% of the shares that may be issued upon settlement of the EPAs awarded for the first and second quarters of 2026.
(3)On February 12, 2026, Dr. Urist entered into a Trading Plan, scheduled to commence on May 14, 2026 and end on May 26, 2026, providing for the sale of up to 27,368 Class A ordinary shares. In addition, on March 25, 2026, Dr. Urist entered into a Trading Plan, scheduled to commence on June 24, 2026…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议